Maintenance treatment with antipsychotic drugs for schizophrenia

作者：Anna Ceraso, Jingxia Lin, Johannes Schneider‐Thoma, Spyridon Siafis, Magdolna Tardy, Katja Komossa, Stephan Heres, Werner Kissling, John M. Davis, Stefan Leucht · 发表于：Cochrane Database of Systematic Reviews · 年份：2020 · DOI：10.1002/14651858.cd008016.pub3 · 被引用次数：177 · 研究领域：Schizophrenia research and treatment、Obsessive-Compulsive Spectrum Disorders、Mental Health and Psychiatry

BACKGROUND: The symptoms and signs of schizophrenia have been linked to high levels of dopamine in specific areas of the brain (limbic system). Antipsychotic drugs block the transmission of dopamine in the brain and reduce the acute symptoms of the disorder. An original version of the current review, published in 2012, examined whether antipsychotic drugs are also effective for relapse prevention. This is the updated version of the aforesaid review. OBJECTIVES: To review the effects of maintaining antipsychotic drugs for people with schizophrenia compared to withdrawing these agents. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials including the registries of clinical trials (12 November 2008, 10 October 2017, 3 July 2018, 11 September 2019). SELECTION CRITERIA: We included all randomised trials comparing maintenance treatment with antipsychotic drugs and placebo for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CIs) on an intention-to-treat basis based on a random-effects model. For continuous data, we calculated mean differences (MD) or standardised mean differences (SMD), again based on a random-effects model. MAIN RESULTS: The review currently includes 75 randomised controlled trials (RCTs) involving 9145 participants comparing antipsychotic medication with placebo. ...